Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06808451 · ClinicalTrials.gov registry record · NA
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
A NA study of Urinary Tract Infections, sponsored by University Hospitals Cleveland Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT06808451: Recruiting NA study of Urinary Tract Infections, sponsored by University Hospitals Cleveland Medical Center.
NCT06808451 is a NA study of Urinary Tract Infections that is actively recruiting participants, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 136 participants, below the 454-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06808451, a NA study of Urinary Tract Infections, is actively recruiting participants, sponsored by University Hospitals Cleveland Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
Adults 18 years or older with urinary tract infection (UTI) symptoms. Participants will be assigned to either the urine culture group or the DNA PCR study group by randomization. At time of enrollment in the study they will be also asked to fill out two questionnaires. If prescribed antibiotics for treatment of a UTI, participants will then be called the day after they are scheduled to stop their antibiotics. Participants will be asked to fill out questionnaires the day after finishing antibiotics. Participants will be enrolled in the study for a maximum of 21 days.
Primary Outcome
The UTI-SIQ-8 is an eight item questionnaire that asks about symptom severity and symptom impairment on a likert scale from 0 to 4, 0 being not at all and 4 being very strong/very severe.
Conditions Studied
Interventions
- DEVICE DNA PCR
- DIAGNOSTIC_TEST Urine Culture
Study Locations (1)
Ohio
- University Hospitals - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT06808451 shows while recruiting
NCT06808451 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 454-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 2 interventions - of which DNA PCR is the first listed.
NCT06808451 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06808451 about?
NCT06808451 is a clinical study titled "Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture". Adults 18 years or older with urinary tract infection (UTI) symptoms. Participants will be assigned to either the urine culture group or the DNA PCR study group by randomization. At time of enrollment in the study they will be also asked to fill out two questionnaires. If prescribed antibiotics for ...
What is the current status of trial NCT06808451?
This trial is currently recruiting. It is a NA study. The enrollment target is 136 participants. The study started on 2025-10-22. Estimated completion is 2026-09-30.
What conditions does trial NCT06808451 study?
This clinical trial studies the following conditions: Urinary Tract Infections.
What interventions are being tested in trial NCT06808451?
The interventions under investigation include: DNA PCR (DEVICE), Urine Culture (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06808451?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06808451 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06808451's enrollment target sits among peer trials
136 21st of 34 higher than 13 of 34 other Urinary Tract Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Tract Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Double Voiding and Post-transplant UTI
RECRUITING · NA
-
Effect of Standardization of Urine Collection Using PEEZY Device as Compared to Clean Peezy for DAB
ACTIVE NOT RECRUITING · NA
-
Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery
ACTIVE NOT RECRUITING · NA
-
Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI